Form 4: Xeris Biopharma Director Bormann-Kennedy Acquires Shares Through Restricted Stock Unit Award

Director Barbara-Jean Anne Bormann-Kennedy acquired 50,000 shares of Xeris Biopharma Holdings, Inc. through a restricted stock unit award.

Summary

• On June 5, 2024, Barbara-Jean Anne Bormann-Kennedy, a director of Xeris Biopharma Holdings, Inc., acquired 50,000 shares of common stock.
• The acquisition was made through a restricted stock unit (RSU) award under the company's 2018 Stock Option and Incentive Plan.
• Each RSU represents a contingent right to receive one share of Xeris Biopharma's common stock.
• The shares will vest in full on the earlier of June 5, 2025, or the date of the company's next annual meeting of stockholders.
• Following the transaction, Bormann-Kennedy directly owns 107,500 shares of Xeris Biopharma common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares suggests confidence, but it's a routine transaction.

Positives

• The acquisition of shares by a director signals confidence in the company's future prospects.
• The vesting schedule aligns the director's interests with those of the shareholders, encouraging long-term value creation.

Future Outlook

The vesting of the restricted stock units is contingent upon future events (June 5, 2025, or the next annual meeting), indicating a forward-looking element tied to the director's continued association with the company.

Industry Context

Stock acquisitions by company directors are common and are often viewed positively by investors as they demonstrate the director's belief in the company's future performance. RSU awards are a typical form of executive compensation.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder sentiment.

Key Dates